Potent inhibition of Lp(a) oxidation by icosapent ethyl (IPE) may have contributed to the cardiovascular risk reduction seen in REDUCE-IT in patients with hypertriglyceridaemia, including those with elevated Lp(a) levels.
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
